Preparation and pharmaceutical evaluation of liposomes entrapping salicylic acid/γ-cyclodextrin conjugate

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 1, 2006, Pages 26-32

  Hagiwara, Yoshiyuki ^a   Arima, Hidetoshi ^a   Miyamoto, Yuji ^a   Hirayama, Fumitoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Complex; Conjugation; Cyclodextrin; Liposome; Residence time; Salicylic acid

Indexed keywords

GAMMA CYCLODEXTRIN DERIVATIVE; LIPOSOME; PHOSPHATE BUFFERED SALINE; SALICYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CELL TRANSPORT; CHEMICAL ANALYSIS; COMPARATIVE STUDY; COVALENT BOND; DRUG BINDING; DRUG CONJUGATION; DRUG DISPOSITION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME DEGRADATION; FREEZE THAWING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; RAT; SOLID STATE; SUSPENSION;

ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHYSICAL; DRUG CARRIERS; DRUG STABILITY; GAMMA-CYCLODEXTRINS; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIPOSOMES; MACROPHAGES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; RATS; SALICYLIC ACID; SUSPENSIONS; TISSUE DISTRIBUTION; X-RAY DIFFRACTION;

EID: 29844451170     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.26     Document Type: Article

References (32)

1. Uekama K., Chem. Pharm. Bull., 52, 900-915 (2004).
2. Crommelin D. J., Storm G., J. Liposome Res., 13, 33-36 (2003).
3. Medina O. P., Zhu Y., Kairemo K., Curr. Pharm. Des., 10, 2981-2989 (2004).
4. Frijlink H. W., Franssen E. J., Eissens A. C., Oosting R., Lerk C. F., Meijer D. K., Pharm. Res., 8, 380-384 (1991).
5. Pitha J., "New Trends in Cyclodextrins and Derivatives," ed. by Duchéne D., Editions de Santé, Paris, 1993, pp. 357-367.
6. Frömming H., Szejtli J., "Cyclodextrins in Pharmacy," ed. by Szejtli J., Kluwer, Dordrecht, 1994, pp. 105-126.
7. Thompson D. O., Crit. Rev. Ther. Drug Carrier Syst., 14, 1-104 (1997).
8. Maesaki S., Curr. Pharm. Des., 8, 433-440 (2002).
9. Wolff A. C., Oncologist, 8 (Suppl. 2), 25-30 (2003).
10. McCormack B., Gregoriadis G., J. Drug Target., 2, 449-454 (1994).
11. McCormack B., Gregoriadis G., Int. J. Pharm., 112, 249-258 (1994).
12. Fatouros D. G., Hatzidimitriou K., Antimisiaris S. G., Eur. J. Pharm. Sci., 13, 287-296 (2001).
13. McCormack B., Gregoriadis G., Biochim. Biophys. Acta, 1291, 237-244 (1996).
14. Uekama K., Minami K., Hirayama F., J. Med. Chem., 40, 2755-2761 (1997).
15. Cheng J., Khin K. T., Jensen G. S., Liu A., Davis M. E., Bioconjug. Chem., 14, 1007-1017 (2003).
16. Hirayama F., Minami K., Uekama K., J. Pharm. Pharmacol., 48, 27-31 (1996).
17. Hirayama F., Ogata T., Yano H., Arima H., Udo K., Takano M., Uekama K., J. Pharm. Sci., 89, 1486-1495 (2000).
18. Yano H., Hirayama F., Arima H., Uekama K., J. Pharm. Sci., 90, 493-503 (2001).
19. Irie T., Uekama K., J. Pharm. Sci., 86, 147-162 (1997).
20. Nishijo J., Mizuno H., Chem. Pharm. Bull., 46, 120-124 (1998).
21. Pick U., Arch. Biochem. Biophys., 212, 186-194 (1981).
22. McLeod A., Friend D., Tozer T., Int. J. Pharm., 92, 105-114 (1993).
23. Hirayama F., Uekama K., "Methods of Investigation and Preparing Inclusion Complexes," ed. by Duchéne D., Editions de Santé, Paris, 1987, pp. 133-172.
24. Mayer L. D., Hope M. J., Cullis P. R., Biochim. Biophys. Acta, 858, 161-168 (1986).
25. Somani B. L., Khanade J., Sinha R., Anal. Biochem., 167, 327-330 (1987).
26. Yamaoka K., Nakagawa T., Uno T., J. Pharcokinet. Biopharm., 6, 547-558 (1978).
27. Ganapathi R., Krishan A., Biochem. Pharmacol., 33, 698-700 (1984).
28. Uekama K., Hirayama F., Irie T., Chem. Rev., 98, 2045-2076 (1998).
29. Gregoriadis G., Trends Biotechnol., 13, 527-537 (1995).
30. Yano H., Hirayama F., Arima H., Uekama K., J. Pharm. Sci., 90, 2103-2112 (2001).
31. Maruyama K., Biosci. Rep., 22, 251-266 (2002).
32. Tomii Y., Curr. Pharm. Des., 8, 467-474 (2002).